2. Search Result
Search Result
Results for "

Anti-ischemic

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

3

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112575
    Tiazotic acid

    		NO Synthase Infection Cardiovascular Disease Inflammation/Immunology
    Tiazotic acid is a metabolic agent that has immunomodulatory, anti-inflammatory, antioxidant, anti-ischemic, cardio- and endothelioprotective, antiplatelet, hepatoprotective activities. Tiazotic acid increases the levels of eNOS. Tiazotic acid also reduces the level of D-dimer in the blood, which reduces the risks of heart attacks and strokes in post-COVID syndrome .
    Tiazotic acid
  • HY-121719
    TIQ-A

    		PARP Cardiovascular Disease Cancer
    TIQ-A is a potent TNKS (poly-ART, PARP) inhibitor, with an IC50 of 24 nM for TNKS2. TIQ-A is a potential anti-ischemic agent .
    TIQ-A
  • HY-142019
    Tanshinol borneol ester

    		Akt AMPK Cardiovascular Disease
    Tanshinol borneol ester, an angiogenesis stimulator, promoted multiple key steps of angiogenesis through Akt and MAPK signalling pathways. Tanshinol borneol ester has anti-ischemic and anti-atherosclerosis activities .
    Tanshinol borneol ester
  • HY-120180
    BMS-188107

    		Calcium Channel Cardiovascular Disease
    BMS-188107 is a calcium antagonist that exerts anti-ischemic effects. BMS-188107 improves postischemic contractile function and reduces lactate dehydrogenase release. BMS-188107 can be utilized in cardiovascular research .
    BMS-188107
  • HY-19463A
    F15845

    		Sodium Channel Cardiovascular Disease
    F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment .
    F15845
  • HY-106865
    Mivazerol

    		Dopamine Receptor Adrenergic Receptor Cardiovascular Disease
    Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol has an anti-ischemic activity. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol can be used for myocardial ischemia research .
    Mivazerol
  • HY-114691
    R 59494

    		Sodium Channel
    R 59494, an anti-ischemic compound, is a potent blocker of Na+ and Ca2+ uptake induced by veratridine intoxication.
    R 59494
  • HY-U00151A
    Dopropidil hydrochloride

    		Calcium Channel Cardiovascular Disease
    Dopropidil hydrochloride is a novel anti-anginal calcium ion modulating agent, possessing intracellular calcium antagonist activity and anti-ischemic effects in several predictive animal models.
    Dopropidil hydrochloride
  • HY-U00151
    Dopropidil

    		Calcium Channel Cardiovascular Disease
    Dopropidil is a novel anti-anginal calcium ion modulating agent, possessing intracellular calcium antagonist activity and anti-ischemic effects in several predictive animal models.
    Dopropidil
  • HY-N13251
    Verbena Extract

    		Others Neurological Disease
    Verbena Extract is a verbena extract. Verbena Extract is a potential anti-ischemic stroke agent, and its mechanism may be related to IL17A-mediated neuroinflammation regulation. .
    Verbena Extract
  • HY-149253
    OY-201

    		Others Neurological Disease
    OY-201 is a potential and BBB-penetrated anti-ischemic stroke agent. OY-201 shows the good safety and neuroprotective activity in both in vitro and in vivo models .
    OY-201
  • HY-19021
    ADD-17014

    		mGluR Neurological Disease
    ADD-17014 is a L-Glu antagonist. ADD-17014 impairs presynaptic excitatory amino acid L-Glu neurotransmission. ADD-17014 is a prodrug of its β-amino alcohol metabolite, and the metabolite acts as a NMDA receptor antagonist by binding to the MK-801 site located inside the NMDA receptor or ion channel. ADD-17014 has an anticonvulsant and anti-ischemic activity. ADD-17014 can be used for neurodegenerative diseases like Parkinson’s disease, Alzheimer’s disease and stroke research .
    ADD-17014
  • HY-114873
    LY256548

    LY25684

    		 Phospholipase COX Lipoxygenase Leukotriene Receptor Inflammation/Immunology
    LY256548 (LY25648) is an orally available anti-ischemic and anti-inflammatory compound with central nervous system activity. LY256548 is an inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and COX, and inhibits A23187 (HY-N6687)-stimulated leukotriene B4 production. LY256548 inhibits bone damage and paw swelling in the rat Freund's complete adjuvant-induced arthritis (FCA) model .
    LY256548
  • HY-175032
    ATF3-IN-1

    		Ferroptosis Epigenetic Reader Domain Reactive Oxygen Species (ROS) Glutathione Peroxidase Cardiovascular Disease Neurological Disease
    ATF3-IN-1 is a ferroptosis and ATF3 inhibitor. ATF3-IN-1 inhibits oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, exerting anti-ischemic stroke effects. ATF3-IN-1 can attenuate ischemia/reperfusion (I/R) injury and improve neuronal survival. ATF3-IN-1 has neuroprotective effects and can be used to study ischemic stroke .
    ATF3-IN-1
  • HY-105084
    Lubeluzole

    		Sodium Channel Calcium Channel Infection Cardiovascular Disease Neurological Disease Cancer
    Lubeluzole is the S-isomer of benzothiazole derivative. Lubeluzole can inhibit glutamate release, glutamate-activated NO synthesis and block voltage-gated Sodium Channel and Calcium Channel. Lubeluzole exhibits anti-ischemic and neuroprotective effects. Lubeluzole also shows anti-bacterial and anti-diarrheal potential. Lubeluzole can inhibit cardiac sodium channel and prolong cardiac action potential. Lubeluzole can inhibit cancer cells proliferation and invasion and shows chemosensitizing effect. Lubeluzole can be used for the researches of cancer, infection, neurological and cardiovascular disease such as stroke, infectious diarrhea and ovarian .
    Lubeluzole
  • HY-105084A
    Lubeluzole dihydrochloride

    		Sodium Channel Calcium Channel Infection Cardiovascular Disease Neurological Disease Cancer
    Lubeluzole dihydrochloride is the dihydrochloride salt of Lubeluzole (HY-105084). Lubeluzole is the S-isomer of benzothiazole derivative. Lubeluzole can inhibit glutamate release, glutamate-activated NO synthesis and block voltage-gated Sodium Channel and Calcium Channel. Lubeluzole exhibits anti-ischemic and neuroprotective effects. Lubeluzole also shows anti-bacterial and anti-diarrheal potential. Lubeluzole can inhibit cardiac sodium channel and prolong cardiac action potential. Lubeluzole can inhibit cancer cells proliferation and invasion and shows chemosensitizing effect. Lubeluzole can be used for the researches of cancer, infection, neurological and cardiovascular disease such as stroke, infectious diarrhea and ovarian .
    Lubeluzole dihydrochloride
  • HY-158204
    CNB-001

    		Lipoxygenase Amyloid-β Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology
    CNB-001 is a potent and orally active 5-lipoxygenase (5-LOX) inhibitor. CNB-001 can decreases 5-LOX expression and increase proteasome activity. CNB-001 can inhibit accumulation of soluble Amyloid-β and ubiquitinated aggregated proteins. CNB-001 can inhibit apoptosis, ROS production and stabilize mitochondrial membrane potential. CNB-001 can reduce insulin resistance and increase glucose uptake. CNB-001 also exhibits anti-ischemic, anti-inflammatory effects. CNB-001 can be used for the researches of inflammation, neurological and metabolic disease, such as Alzheimer's disease, stroke and diabetes .
    CNB-001
  • HY-N9602
    6,7,4'-Trihydroxyflavanone

    		Others Inflammation/Immunology
    6,7,4'-Trihydroxyflavanone is a compound with multiple pharmacological activities, including anti-rheumatic, anti-ischemic, anti-inflammatory, anti-osteoclastogenic and protective T-cells from METH-induced deactivation. 6,7,4'-Trihydroxyflavanone has shown potential protective effects in neurotoxicity studies and can be used to inhibit patients with neurodegenerative diseases caused by METH. 6,7,4'-Trihydroxyflavanone inhibits METH-induced neurotoxicity by upregulating the Nrf2/HO-1 and PI3K/Akt/mTOR signaling pathways. 6,7,4'-Trihydroxyflavanone can also induce Nrf2 nuclear translocation and HO-1 expression, further enhancing its protective effect on neuronal cells .
    6,7,4'-Trihydroxyflavanone
  • HY-106688
    Alinidine

    St-567

    		 Potassium Channel Cardiovascular Disease
    Alinidine (St-567) is a specific bradycardic agent. Alinidine reduces the slope of the diastolic depolarization in sinoatrial tissue and Purkinje fibers. Alinidine shows antiischemic and antiarrhythmic effects .
    Alinidine
  • HY-106688A
    Alinidine hydrobromide

    St-567 hydrobromide

    		 Potassium Channel Cardiovascular Disease
    Alinidine (St-567) hydrobromide is a specific bradycardic agent. Alinidine hydrobromide reduces the slope of the diastolic depolarization in sinoatrial tissue and Purkinje fibers. Alinidine hydrobromide shows antiischemic and antiarrhythmic effects .
    Alinidine hydrobromide
  • HY-107335
    Aplodan

    Creatinol O-phosphate; Creatinol phosphate; Creatinolfosfate

    		 Biochemical Assay Reagents Cardiovascular Disease
    Aplodan (Creatinol O-phosphate) is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or acute myocardial infarction .
    Aplodan
  • HY-108502
    KC 12291 hydrochloride

    		Sodium Channel Cardiovascular Disease
    KC 12291 hydrochloride is an orally active blocker of voltage-gated sodium channel (VGSC). KC 12291 hydrochloride reduces the amplitude of sustained Na + current to exert antiischemic activity. KC 12291 hydrochloride has significant cardioprotective effect in vitro and in vivo .
    KC 12291 hydrochloride
  • HY-103247
    EMD 66684

    		Angiotensin Receptor Cardiovascular Disease
    EMD 66684 is an antagonist of Angiotensin II Type 1 (AT1) receptor. EMD 66684 shows potent binding affinities for the AT1 subtype Ang II receptor with an IC50 value of 0.7 nM. EMD 66684 also serves as an antiischemic cytoprotectant - .
    EMD 66684
  • HY-105022
    Sabeluzole

    R 58735

    		 Tau Protein Neurological Disease
    Sabeluzole (R 58735), a benzothiazol derivative, has antiischemic, antiepileptic, and cognitive-enhancing properties. Sabeluzole protects rat hippocampal neurons against NMDA- and glutamate-induced neurotoxicity via preventing tau expression. Sabeluzole enhances memory in rats, and prevents the amnesic effect of Chlordiazepoxide. Sabeluzole can be used fro research of Alzheimer's disease .
    Sabeluzole
  • HY-108972
    SQ 29548

    		Prostaglandin Receptor Metabolic Disease
    SQ 29548, a high affinity radioligand, is a selective thromboxane-prostanoid (TP) receptor antagonist .
    SQ 29548
  • HY-105022R
    Sabeluzole (Standard)

    R 58735 (Standard)

    		 Reference Standards Tau Protein Neurological Disease
    Sabeluzole (Standard) is the analytical standard of Sabeluzole. This product is intended for research and analytical applications. Sabeluzole (R 58735), a benzothiazol derivative, has antiischemic, antiepileptic, and cognitive-enhancing properties. Sabeluzole protects rat hippocampal neurons against NMDA- and glutamate-induced neurotoxicity via preventing tau expression. Sabeluzole enhances memory in rats, and prevents the amnesic effect of Chlordiazepoxide. Sabeluzole can be used fro research of Alzheimer's disease .
    Sabeluzole (Standard)
  • HY-136182A
    YM-244769

    		Na+/Ca2+ Exchanger Cardiovascular Disease Neurological Disease
    YM-244769 is a potent, selective and orally active Na +/Ca 2+ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca 2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice .
    YM-244769
  • HY-107659
    YM-244769 hydrochloride

    		Na+/Ca2+ Exchanger Cardiovascular Disease Neurological Disease
    YM-244769 hydrochloride is a potent, selective and orally active Na +/Ca 2+ exchanger (NCX) inhibitor. YM-244769 hydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca 2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 hydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 hydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .
    YM-244769 hydrochloride
  • HY-136182
    YM-244769 dihydrochloride

    		Na+/Ca2+ Exchanger Cardiovascular Disease Neurological Disease
    YM-244769 dihydrochloride is a potent, selective and orally active Na +/Ca 2+ exchanger (NCX) inhibitor. YM-244769 dihydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca 2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 dihydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 dihydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .
    YM-244769 dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: